Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
暂无分享,去创建一个
G. MacBeath | H. Hirte | I. Vergote | I. Ray-Coquard | R. Coleman | D. Cibula | P. Harter | S. Siena | J. Pearlberg | F. Selle | A. Poveda | A. Czibere | Joyce F. Liu | R. Naumann | E. Pujade-Lauraine | L. Gladieff | I. Tabah-Fisch | F. Hilpert | F. Raspagliesi | J. D. Del Campo | V. Moyo | K. Riahi | R. Nering | W. Kubasek | B. Adiwijaya
[1] M. Sliwkowski,et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] F. Khuri,et al. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma , 2015, Cancer.
[3] A. Reuss,et al. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Jane Fridlyand,et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.
[5] Birgit Schoeberl,et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. , 2010, Cancer research.
[6] C. Bokemeyer,et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. , 2012, European journal of cancer.
[7] Birgit Schoeberl,et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. , 2010, Cancer cell.
[8] M. Bookman,et al. Second-line treatment of ovarian cancer. , 2000, The oncologist.
[9] R. Coleman,et al. Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer , 2011, Drugs.
[10] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[11] Carlos L. Arteaga,et al. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors , 2011, Proceedings of the National Academy of Sciences.
[12] B. Monk,et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Oncology.
[13] R. Govindan,et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. MacBeath,et al. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. , 2013, The American journal of pathology.
[15] M. Ayers,et al. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. , 2015, Journal of the National Cancer Institute.
[16] A. Ullrich,et al. Inhibition of doxorubicin‐induced HER3‐PI3K‐AKT signalling enhances apoptosis of ovarian cancer cells , 2012, Molecular oncology.
[17] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[18] J. Thigpen,et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] V. Grantcharova,et al. Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.
[20] J. Stenvang,et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant , 2009, Breast Cancer Research and Treatment.
[21] B. Weber,et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] B. Karlan,et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] N. Hellyer,et al. Heregulin-dependent Activation of Phosphoinositide 3-Kinase and Akt via the ErbB2/ErbB3 Co-receptor* , 2001, The Journal of Biological Chemistry.
[24] L. Sequist,et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. , 2014 .
[25] Dhara N. Amin,et al. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. , 2010, Seminars in cell & developmental biology.
[26] Daniel J. Freeman,et al. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer , 2015, EBioMedicine.
[27] G. MacBeath,et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. , 2014 .
[28] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.
[29] L. Trusolino,et al. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies , 2014, Journal of Molecular Medicine.
[30] Xiaoping Yang,et al. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer , 2013, Breast Cancer Research.
[31] Keunchil Park,et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.